Methods for deformulating drugs

October 25, 2018

The FDA has a number of regulatory routes through which a company can seek approval for a generic drug. The most notable is the Abbreviated New Drug Application (ANDA) route whereby a generic company develops an exact copy of the innovator product and can use the safety and efficacy data from the innovator in their submission. This route was facilitated in the 1980s through the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act after Senator Orrin Hatch and Representative Henry Waxman who sponsored it. The US government at the time were concerned about the low number of generic drug approvals. Before the Hatch-Waxman act, innovator companies could easily create legal obstacles for companies looking to develop generic medicines; this made generic drug development an unattractive industry. The Hatch-Waxman Act removed many of these obstacles, successfully incentivising generics companies to produce affordable generic medicines, whilst simultaneously protecting innovator companies by allowing them a sufficient exclusivity period after the initial release of their drug and keep innovation profitable.

Spotlight

Dong-A Pharmaceutical Co.,Ltd

Established in 1932, Dong-A Pharm. has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of our society. Headquartered in South Korea, Dong-A Pharm. employs over 2,300 people worldwide.

OTHER WHITEPAPERS
news image

Modernizing Pharma Operations With Process Analytical Technology

whitePaper | November 18, 2022

It’s the same for manufacturers across industries and across the globe; there’s a steadily increasing pressure to meet market demand, despite facing new challenges andconstraints.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

DEVELOPING AND OPTIMIZING CLEANING PROCESSES

whitePaper | November 1, 2022

Equipment cleaning in manufacturing companies is often not given the same emphasis as other processes. It can be viewed as a task.

Read More
news image

NEXTGEN PHARMA TAKES ‘SMART’ STRIDES WITH INTERNET OF THINGS

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

Read More
news image

MOLECULAR GLUES LANDSCAPE IN DRUG DISCOVERY

whitePaper | June 21, 2022

nduced-proximity targeted protein degradation (TPD) is a ground-breaking strategy in drug discovery that has emerged during the last decade.

Read More
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More

Spotlight

Dong-A Pharmaceutical Co.,Ltd

Established in 1932, Dong-A Pharm. has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of our society. Headquartered in South Korea, Dong-A Pharm. employs over 2,300 people worldwide.

Events